Zevra Therapeutics(NASDAQ) ZVRA

Zevra Therapeutics, Inc. makes medicines for people with rare diseases. These treatments help patients manage serious conditions with few options. The company turns scientific research into usable therapies.

Pills for Rare Conditions

• MIPLYFFA: FDA-approved oral treatment used with other medication for neurological symptoms of Niemann-Pick disease type C.
• OLPRUVA: Approved powder medication for the chronic management of certain urea cycle disorders in adults and children.
• Celiprolol: Investigational drug candidate currently undergoing a Phase 3 clinical trial for patients with Vascular Ehlers-Danlos Syndrome.

Strategic Moves and Milestones

• Completed the acquisition of Acer Therapeutics in Nov. 2023 to add new products and clinical candidates.
• Sold a rare pediatric disease priority review voucher for $148.3 million in Apr. 2025.
• Finalized a settlement agreement in March 2026 to sell the rights for the SDX product portfolio.
• Repaid $63.1 million in outstanding debt obligations in March 2026 to clear the senior secured loan facility.

What Makes Zevra Different?

Zevra uses proprietary Ligand Activated Therapy to create prodrugs, which are inactive substances that convert into active medicine inside the body. The company also manages a global program that provides experimental treatments to patients while pursuing formal regulatory approvals.

Financial Performance at a Glance

• Revenue was $75.9 million for the six-month period ended June 30, 2026, up $29.6 million year over year.
• Net income reached $46.6 million during the six-month period ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $260.2 million as of June 30, 2026.
• Net cash provided by operating activities was $23.2 million for the six-month period ended June 30, 2026.

The Big Picture

Zevra has evolved from a research-focused firm into a commercial business with multiple approved rare disease treatments. The company focuses on specialized therapies and strategic asset sales to maintain its financial position and pipeline development.